Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[Ac-225]-PSMA-62 in Prostate Cancer (ACCEL)
NCT06229366Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Sep 2027
- Modality
- Alpha Emitters, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Ac-225-PSMA-62 in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Recommended Phase II Dose and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
Ac-225-PSMA-62
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06229366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229366.